More than $50 million in fines has been issued to drug giant Sanofi by France’s Antitrust Authority for what the regulator called a ‘smear campaign’ by the pharmaceutical company against generics drugs. Reports say the Authority found that Sanofi hampered competition by encouraging doctors and pharmacies to provide its brand name blood thinner drug Plavix instead of the generic form. Sanofi said it will appeal the fine. According to reports, Sanofi has looked to up profits since patent protection ended for two of its top-earning drugs, Plavix and blook pressure drug Avapro.
Featured News
EU Moves to Rein in National Interference in Corporate Mergers
Mar 18, 2026 by
CPI
Germany Targets Fuel Price Spikes With New Daily Cap on Increases
Mar 17, 2026 by
CPI
Visa and Mastercard Win Right to Appeal UK Ruling on Interchange Fees
Mar 17, 2026 by
CPI
Spain’s Antitrust and Energy Watchdog to Release Blackout Report Without Blame
Mar 17, 2026 by
CPI
White House, GOP Again Trying to Enact Federal Preemption of State AI Laws
Mar 17, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Behavioral Economics
Feb 22, 2026 by
CPI
Behavioral Antitrust in 2026
Feb 22, 2026 by
Maurice Stucke
Behavioral Economics in Competition Policy: Going Beyond Inertia and Framing Effects
Feb 22, 2026 by
Annemieke Tuinstra & Richard May
Agreeing to Disagree in Antitrust
Feb 22, 2026 by
Jorge Padilla
Recognizing What’s Around the Corner: Merger Control, Capabilities, and the New Nature of Potential Competition
Feb 22, 2026 by
Magdalena Kuyterink & David J. Teece